Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

UBS
US Department of Justice
Citi
Moodys
Fuji
Daiichi Sankyo

Generated: September 19, 2019

DrugPatentWatch Database Preview

Patent: 9,476,062

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,476,062
Title:Methods and compositions relating to improved lentiviral vectors and their applications
Abstract: The present invention provides HIV-derived lentivectors which are safe, highly efficient, and very potent for expressing transgenes for human gene therapy, especially, in human hematopoietic progenitor cells as well as in all other blood cell derivatives. The lentiviral vectors comprise a self-inactivating configuration for biosafety and promoters such as the EF1.alpha. promoter as one example. Additional promoters are also described. The vectors can also comprise additional transcription enhancing elements such as the wood chuck hepatitis virus post-transcriptional regulatory element. These vectors therefore provide useful tools for genetic treatments such as inherited and acquired lympho-hematological disorders, gene-therapies for cancers especially the hematological cancers, as well as for the study of hematopoiesis via lentivector-mediated modification of human HSCs.
Inventor(s): Trono; Didier (Vufflens-le-Chateau, CH), Salmon; Patrick (Arenthon, FR)
Assignee: Research Development Foundation (Carson City, NV)
Application Number:14/693,406
Patent Claims:see list of patent claims

Details for Patent 9,476,062

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04 ➤ Sign Up Research Development Foundation (Carson City, NV) 2020-11-13 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04 ➤ Sign Up Research Development Foundation (Carson City, NV) 2020-11-13 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04 ➤ Sign Up Research Development Foundation (Carson City, NV) 2020-11-13 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Medtronic
McKinsey
UBS
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.